257 related articles for article (PubMed ID: 17324968)
1. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists.
Carmona L; Descalzo MA; Perez-Pampin E; Ruiz-Montesinos D; Erra A; Cobo T; Gómez-Reino JJ;
Ann Rheum Dis; 2007 Jul; 66(7):880-5. PubMed ID: 17324968
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
[TBL] [Abstract][Full Text] [Related]
3. Cancer in patients with rheumatic diseases exposed to TNF antagonists.
Carmona L; Abasolo L; Descalzo MA; Pérez-Zafrilla B; Sellas A; de Abajo F; Gomez-Reino JJ; ;
Semin Arthritis Rheum; 2011 Aug; 41(1):71-80. PubMed ID: 21093020
[TBL] [Abstract][Full Text] [Related]
4. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
Jacobsson LT; Turesson C; Gülfe A; Kapetanovic MC; Petersson IF; Saxne T; Geborek P
J Rheumatol; 2005 Jul; 32(7):1213-8. PubMed ID: 15996054
[TBL] [Abstract][Full Text] [Related]
5. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
[TBL] [Abstract][Full Text] [Related]
6. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
Gómez-Reino JJ; Carmona L; Angel Descalzo M;
Arthritis Rheum; 2007 Jun; 57(5):756-61. PubMed ID: 17530674
[TBL] [Abstract][Full Text] [Related]
7. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.
Jacobsson LT; Turesson C; Nilsson JA; Petersson IF; Lindqvist E; Saxne T; Geborek P
Ann Rheum Dis; 2007 May; 66(5):670-5. PubMed ID: 17158824
[TBL] [Abstract][Full Text] [Related]
8. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis.
Sakai R; Komano Y; Tanaka M; Nanki T; Koike R; Nagasawa H; Amano K; Nakajima A; Atsumi T; Koike T; Ihata A; Ishigatsubo Y; Saito K; Tanaka Y; Ito S; Sumida T; Tohma S; Tamura N; Fujii T; Sugihara T; Kawakami A; Hagino N; Ueki Y; Hashiramoto A; Nagasaka K; Miyasaka N; Harigai M;
Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1125-34. PubMed ID: 22422487
[TBL] [Abstract][Full Text] [Related]
9. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients.
Thyagarajan V; Norman H; Alexander KA; Napalkov P; Enger C
Semin Arthritis Rheum; 2012 Dec; 42(3):223-33. PubMed ID: 22748510
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis.
Al-Aly Z; Pan H; Zeringue A; Xian H; McDonald JR; El-Achkar TM; Eisen S
Transl Res; 2011 Jan; 157(1):10-8. PubMed ID: 21146146
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
[TBL] [Abstract][Full Text] [Related]
12. Long-term mortality rate in rheumatoid arthritis patients with disease onset in the 1980s.
Kapetanovic MC; Lindqvist E; Geborek P; Saxne T; Eberhard K
Scand J Rheumatol; 2011 Nov; 40(6):433-8. PubMed ID: 21619489
[TBL] [Abstract][Full Text] [Related]
13. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven RF; Klareskog L
Ann Rheum Dis; 2007 Oct; 66(10):1339-44. PubMed ID: 17261532
[TBL] [Abstract][Full Text] [Related]
14. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
15. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Romanus V; Klareskog L; Feltelius N
Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370
[TBL] [Abstract][Full Text] [Related]
16. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Ann Rheum Dis; 2005 Oct; 64(10):1421-6. PubMed ID: 15829572
[TBL] [Abstract][Full Text] [Related]
17. Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy.
Peña-Sagredo JL; Fariñas MC; Perez-Zafrilla B; Cruz-Valenciano A; Crespo M; Joven-Ibañez B; Riera E; Manero-Ruiz FJ; Chalmeta I; Hernández MV; Rodríguez-Gómez M; Maíz O; López R; Cobo T; Pita J; Carmona L; Gonzalez-Gay MA;
Clin Exp Rheumatol; 2009; 27(6):920-5. PubMed ID: 20149306
[TBL] [Abstract][Full Text] [Related]
18. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?
Gonzalez A; Maradit Kremers H; Crowson CS; Ballman KV; Roger VL; Jacobsen SJ; O'Fallon WM; Gabriel SE
Ann Rheum Dis; 2008 Jan; 67(1):64-9. PubMed ID: 17517756
[TBL] [Abstract][Full Text] [Related]
19. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0.
Gómez-Reino JJ; Rodríguez-Lozano C; Campos-Fernández C; Montoro M; Descalzo MÁ; Carmona L;
Ann Rheum Dis; 2012 Mar; 71(3):382-5. PubMed ID: 21998116
[TBL] [Abstract][Full Text] [Related]
20. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry.
Pallavicini FB; Caporali R; Sarzi-Puttini P; Atzeni F; Bazzani C; Gorla R; Marchesoni A; Favalli EG; Montecucco C
Autoimmun Rev; 2010 Jan; 9(3):175-80. PubMed ID: 19647103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
